Dr. D. CBD

Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion.
Sep
22
2018

Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion.

The potential use of cannabidiol in the therapy of metabolic syndrome
Sep
20
2018

The potential use of cannabidiol in the therapy of metabolic syndrome

A Systematic Review and Meta-Analysis of the Haemodynamic Effects of Cannabidiol.
Sep
4
2018

A Systematic Review and Meta-Analysis of the Haemodynamic Effects of Cannabidiol.

A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study.
Sep
4
2018

A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study.

Is the cardiovascular system a therapeutic target for cannabidiol?
Sep
4
2018

Is the cardiovascular system a therapeutic target for cannabidiol?

Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy.
Jun
2
2018

Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy.

Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.
May
28
2018

Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications.
May
28
2018

The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications.

Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.
May
28
2018

Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.

Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies.
May
27
2018

Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies.